Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: A review of clinical trials

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 535-548

  Takimoto, Chris H ^a   Awada, Ahmad ^b  

^a South Texas Accelerated Research Therapeutics   (United States)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chemotherapy; Combination; Phase I II clinical trials; Solid tumors; Sorafenib; Targeted agent

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DESQUAMATION; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE TOXICITY; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPHIL TOXICITY; PRIORITY JOURNAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINORRHEA; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PYRIDINES;

EID: 38049019119     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0639-9     Document Type: Review

References (51)

1. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22
2. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
3. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
4. Kane RC, Farrell AT, Saber H et al (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278
5. Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437
6. Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512
7. Chatelut E, Delord JP, Canal P (2003) Toxicity patterns of cytotoxic drugs. Invest New Drugs 21:141-148
8. Mewani RR, Tang W, Rahman A et al (2004) Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. Int J Oncol 24:1181-1188
9. Pei J, Zhang C, Gokhale PC et al (2004) Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs 15:243-253
10. Mickisch GH (1994) Chemoresistance of renal cell carcinoma: 1986-1994. World J Urol 12:214-223
11. Vincent P, Zhang X, Chen C et al (2003) Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, vinorelbine, gemcitabine or doxorubicin. Proc Am Assoc Cancer Res 44:164
12. Vincent R, Bernando V, Chen C, Zhang X, Carter C (2003) Chemotherapy with BAY 43-9006 in combination with Irinotecan or administered as repeated cycles of therapy against the DLD-1 human tumor xenograft. Clin Cancer Res 44:4469 (Abstract)
13. Richly H, Kupsch P, Passage K et al (2004) Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 42:650-651
14. Richly H, Henning BF, Kupsch P et al (2006) Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17:866-873
15. Eisen T, Ahmad T, Marais R et al (2005) Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma. Eur J Cancer Suppl 3:349
16. Kupsch P, Henning BF, Passarge K et al (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196
17. Figer A, Moscovici M, Bulconic S et al (2004) Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors. Ann Oncol 15:iii87 (Abstract 327)
18. Siu LL, Awada A, Takimoto CH et al (2006) Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:144-151
19. Flaherty KT, Lee RJ, Humphries R, O'Dwyer PJ, Schiller J (2003) Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc Am Soc Clin Oncol 22:710
20. Robert C, Lassau N, Angevin E et al (2005) Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. Eur J Cancer Suppl 3:254
21. Adjei AA, Mandrekar S, Marks RS et al (2005) A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non small cell lung cancer (NSCLC). J Clin Oncol 23:208s
22. Steinbild S, Baas F, Gmehling D et al (2005) Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J Clin Oncol 23:3115 (Abstract)
23. Azad NS, Posadas EM, Kwitkowski VE et al (2006) Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol 24:3004 (Meeting Abstracts)
24. Posadas EM, Kwitkowski V, Liel MS et al (2005) Clinical synergism from combinational VEGF signal transduction inhibition in patients with advanced solid tumors - early results from a Phase I study of sorafenib (BAY 43-9006) and bevacizumab. Eur J Cancer Suppl 3:419
25. Duran I, Hotte S, Chen E et al (2007) Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors. Eur J Cancer (supp) 4:167
26. Flaherty KT, Brose M, Schuchter LM et al (2006) Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: PFS and response versus B-Raf status. Ann Oncol 17:iii33
27. Schiller JH, Flaherty KT, Redlinger M et al (2006) Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J Clin Oncol 24:7194 (Meeting Abstracts)
28. Lorigan P, Corrie P, Chao D et al (2006) Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J Clin Oncol 24:8012 (Meeting Abstracts)
29. Adjei AA, Argiris A, Murren JR (1999) Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Semin Oncol 26:32-40
30. Amaravadi RK, Schuchter LM, Kramer A et al (2006) Preliminary results of a randomized phase II study comparing two schedules of temzolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 24(Part 1):8009 (Meeting Abstracts)
31. Gollob J, Richmond T, Jones J et al (2006) Phase II trial of sorafenib plus interferon-alpha 2b (IFN-{alpha}2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol 24:4538 (Meeting Abstracts)
32. Ryan CW, Goldman BH, Lara PN Jr et al (2006) Sorafenib plus interferon-{alpha}2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J Clin Oncol 24:4525 (Meeting Abstracts)
33. Flaherty KT, Brose M, Schuchter L et al (2004) Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol 22:7507 (Abstract)
34. Keilholz U, Punt CJ, Gore M et al (2005) Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747-6755
35. Welch S, Hirte H, Schilder RJ et al (2006) Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. J Clin Oncol 24:5084 (Meeting Abstracts)
36. Strumberg D, Awada A, Hirte H et al (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42:548-556
37. Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6:835-846
38. Odabaei G, Chatterjee D, Jazirehi AR et al (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91:169-200
39. Wang HG, Miyashita T, Takayama S et al (1994) Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9:2751-2756
40. Yu C, Bruzek LM, Meng XW et al (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24:6861-6869
41. Kim SH, Lee SH, Kwak NH, Kang CD, Chung BS (1996) Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 98:199-205
42. Cornwell MM, Smith DE (1993) A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 268:15347-15350
43. Erhardt P, Schremser EJ, Cooper GM (1999) B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19:5308-5315
44. Karasarides M, Chiloeches A, Hayward R et al (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-6298
45. Chapman PB, Einhorn LH, Meyers ML et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751
46. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG (2002) Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25:283-286
47. Zimpfer-Rechner C, Hofmann U, Figl R et al (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13:531-536
48. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl 1):2-10
49. Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69(Suppl 3):11-16
50. Gridelli C, Rossi A, Mongillo F et al (2007) A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer 8:396-398
51. Sosman JA, Flaherty K, Atkins MB et al (2006) A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol 24:3031 (Meeting Abstracts)